Hanmi Pharmaceutical said its board decided to cancel 85,316 treasury shares it holds (filed October 27, 2026).

Hanmi Pharmaceutical said in a filing that its board on October 27, 2026 decided to cancel 85,316 common shares it holds as treasury stock. The company said the cancellation falls under the proviso of Article 343, Paragraph 1 of the revised Commercial Act, and will be carried out by board resolution without a capital reduction procedure, regardless of the reason for acquiring the shares. The planned cancellation amount is KRW 28.3 billion, and the planned cancellation date is November 2, 2026; the company said this may change depending on consultations with relevant authorities and other factors.

1. 01

   The shares to be cancelled are treasury shares the company acquired earlier, and the company said the cancellation will be carried out by board resolution without a capital reduction procedure.

2. 02

   The company said the planned cancellation amount of KRW 28.3 billion is based on the book value of the shares to be cancelled.

3. 03

   The company said the planned cancellation date of November 2, 2026 may change depending on consultations with relevant authorities and other factors.

4. 04

   The company said this filing also serves as notice of the disposal of treasury shares.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Common shares to be cancelled

85,316 shares

Planned cancellation amount

KRW 28.3 billion

Value per share

KRW 2,500

Total issued common shares

12,810,991 shares

Planned cancellation date

November 2, 2026

Filing facts

Filing type

Share Cancellation

Report name

Decision on Share Cancellation

Filed

Oct 27, 2026

Receipt number

20261027800662